What? When? Why?

As per our report, the size of the global infectious disease diagnostics market is estimated to be worth USD 26.54 billion by 2026 from USD 18.15 billion in 2021, growing at a CAGR of 7.9% from 2021 to 2026.

Infectious disease is a term used to describe a condition caused by a diagnostic laboratory test used to diagnose infectious diseases with the assistance of competent technicians and physicians. It is a diagnostic process that identifies and characterizes the infectious disease's causal organism. To further diagnose the disease, molecular diagnostic tests are utilized to detect specific sequences in DNA or RNA, such as single nucleotide polymorphisms (SNPs), deletions, rearrangements, insertions, and others. These techniques combine to analyze biological indicators at the molecular level, such as the genome and proteome. Thus, molecular diagnostics is a technique for detecting and identifying genetic elements and proteins connected to particular health conditions and diseases and infectious microorganisms in body fluids such as blood, urine, or sputum. For infectious disease testing, hospitals, academic institutions, laboratories, and others use molecular diagnostics.

Impact of COVID-19 on the global infectious disease diagnostics market:

COVID-19 is a newly identified novel coronavirus that causes infectious sickness. COVID-19, which was mainly unknown until its emergence in Wuhan, China, in December 2019, went from a regional problem to a global pandemic in weeks. The COVID-19 pandemic had a negative influence on most companies' overall sales. Still, it had a favorable impact on the infectious disease diagnostics industry since diagnostic procedures were used for COVID-19 testing. In research institutes, the use of molecular diagnostics is growing. Techniques like PCR, western blotting, and southern blotting are becoming more popular. Furthermore, the global spread of SARS-CoV-2 infection has resulted in an upsurge in government and diagnostic company research funding in the search for novel molecular diagnostics.

Molecular diagnostics provide precise and effective outcomes. Furthermore, these tests allow for the early diagnosis of diseases, reducing the risk of replacement. The high costs of these tests, on the other hand, are likely to induce patients to seek out other alternatives. Furthermore, the rate of internal substitution for detecting emerging diseases, such as SARS-CoV-2, is high, boosting competitive rivalry. The global incidence of infectious diseases and the emergence of COVID-19, raising awareness for early disease identification, a shift in focus from centralized laboratories to decentralized POC testing, and technical improvements are driving market expansion. Apart from COVID-19 tests, these labs also perform additional infectious illness diagnosis tests such as HIV, hepatitis, TB, and dengue fever. Furthermore, rising public awareness of the importance of early detection and management of infectious diseases, as well as an increase in the number of information technology systems used to develop advanced diagnostic devices, are expected to provide lucrative opportunities for the global infectious disease molecular diagnostics market to grow during the forecast period.

DRIVING FACTORS:

Increased prevalence of infectious diseases such as hepatitis, influenza, COVID-19, and human immunodeficiency virus (HIV); increased demand for point-of-care diagnostic tests; increased funding from private and government organizations for diagnostic service centers; and advancements in infectious disease diagnostic technologies are driving the global infectious disease diagnostics market. The rising number of prescriptions for infectious disease diagnostic tests is due to diagnosing and managing such disorders. These factors, combined with the growing tendency toward preventative care, are projected to increase demand for infectious disease diagnostics during the forecast period. Compared to other standard diagnostic tests, new technologies such as INAAT, mass spectroscopy, and ISH have a low false-positive rate. Advantages such as the technology's cost-effectiveness and user-friendliness, as well as the accuracy it provides, are expected to boost adoption.

Rapid technical developments in portability, accuracy, and cost-effectiveness are expected to be significant market drivers for infectious disease molecular diagnostics. Companies are improving their products by using new processes to obtain more precise and accurate outcomes. With expanded R&D initiatives for generating novel kits to target emerging diseases or engaging in agreements with other kit manufacturing companies, key players are updating their product portfolio for PCR equipment. In addition, infectious disease prevalence in both established and developing nations boosts the infectious disease diagnostics market's growth.

RESTRAINING FACTORS:

Inadequate reimbursement is a significant impediment to the infectious disease diagnostics market expansion. Most diagnostic companies have difficulty commercializing their tests and convincing health insurers to pay for them. During the forecast period, the market is likely to be restricted by high diagnostic instrument costs and a scarcity of competent technicians.

REGIONAL ANALYSIS:

During the forecast period, Asia's expanding elderly population, combined with high untapped opportunities, is likely to drive the region's market for infectious disease molecular diagnostics. In addition, increased access to healthcare in developing countries accounts for the market's high growth rate for infectious disease molecular diagnostics in the Asia Pacific. This is due to changing infectious disease research and development efforts, increased government support, increased public awareness of infectious diseases and their diagnostic techniques, and improved healthcare infrastructure in the region. In addition, the rise of molecular diagnostics in infectious disease testing in Asia is projected to be influenced by the expanding population and economies of developing countries such as India and China. Because of the high incidence and highly inhabited areas, the COVID-19 pandemic has put a significant burden on molecular diagnostics in this region. This region, dominated by China and India, is home to about half of the world's population.

North America has the world's largest infectious disease diagnostics market. The highly developed healthcare systems in the United States and Canada and the presence of multiple major national clinical laboratories, and easy access to technologically advanced instruments all contribute to the market's growth. In addition, the rise in infectious disease and cancer cases in the United States has shifted the trend away from traditional diagnostic approaches and toward molecular diagnostics. The use of molecular tests in conjunction with pharmacogenomics has made early detection of certain disorders possible, which is projected to drive market expansion.

COMPETITIVE LANDSCAPE:

Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson, and Company, Cepheid, Inc.m, Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc. are a few of the notable companies operating in the global infectious disease diagnostics market.

RECENT MARKET DEVELOPMENTS:

• Roche Diagnostics released the Cobas SARS-CoV-2 Variant Set 1 Test in March 2021 to aid in the monitoring of developing coronavirus mutations.
• Thermo Fisher Scientific Purchased Mesa Biotech (US) in February 2021 to enhance the benefits of molecular diagnostics at the point of care.
• Bruker Corporation announced the launch of FluoroType, a winter four-plex PCR panel that can identify RSV, Flu, and SARS-CoV-2, in December 2020.
• Neuberg Diagnostic, a prominent provider of best-in-class laboratories, opened a clinical laboratory in the United States in May 2021 to provide genomic and molecular diagnostics using next-generation sequencing technologies.
• Abbott, a worldwide healthcare organization, announced the launch of the Abbott ID NOW COVID-19 test in March 2020. The Abbott ID NOW COVID-19 test is a molecular point-of-care test that can identify COVID-19 in as little as 5 minutes.
• BD announced the launch of its Influenza A+B and SARS-CoV-2 in a single CE-marked test in February 2021. In the same month, the FDA issued a EUA for the product. The product's capacity to test for both Flu and COVID-19 offers it an edge over its competitors.

MARKET SEGMENTATION:

By Product:

• Instruments
• Reagents
• Services
• Software

By Application:

• Hepatitis B
• Hepatitis C
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Chlamydia trachomatis
• Neisseria gonorrhoeae (CT/NG)
• Human papillomavirus (HPV)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• and others (Influenza, Ebola, Typhoid, Malaria, and Dengue)

By Technology:

• PCR
• INAAT
• DNA Sequencing
• Hybridization

By Traditional methods:

• Immunodiagnostics
• Microscopy
• Biochemical Characterization

By End User:

• Hospital
• Laboratories

By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

BROWSE REGIONAL REPORTS:

• North America Infectious Disease Diagnostics Market
• Europe Infectious Disease Diagnostics Market
• APAC Infectious Disease Diagnostics Market
• Latin America Infectious Disease Diagnostics Market
• MEA Infectious Disease Diagnostics Market